• Sellas Life Sciences is trading at $12.85 (-4.89%) today, extending a sharp pullback from early July trading.
  • The decline comes as investors continue to weigh the progress of the pivotal Phase 3 REGAL trial for its lead cancer immunotherapy, galinpepimut-S (GPS), which recently reached 78 of 80 required events, signaling an imminent data readout.
  • Conflicting analyst views are influencing sentiment, with some highlighting the delay in events as a positive indicator of patient survival, while others express skepticism regarding the trial's success probability and patient selection criteria.